ABVC BioPharma, Inc.
ABVC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 234.3% | -84.3% | 172.6% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 99.9% | -98.1% | 70.5% | 98.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -852.2% | -4,153.2% | -1,567% | -3,083.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -962.1% | -5,109.3% | -1,693.5% | -3,608.5% |
| EPS Diluted | -0.42 | -1.8 | -5.2 | -5.1 |
| % Growth | 76.7% | 65.4% | -2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |